Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAR2CSA vaccine
- Development stage
- Unknown
- Lead developer
- European Vaccine Initiative
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
VAR2CSA vaccine refers to a class of placental malaria vaccine candidates designed to elicit protective antibodies against VAR2CSA, a member of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family. VAR2CSA is expressed on the surface of infected erythrocytes and mediates their sequestration in the placenta by binding to the host receptor chondroitin sulfate A (CSA), leading to severe pregnancy outcomes such as maternal anemia, low birth weight, and stillbirth. Leading VAR2CSA-based vaccine candidates include PRIMVAC (developed by Inserm) and PAMVAC (developed by the University of Copenhagen), both of which have completed Phase I clinical trials. Next-generation candidates, such as HPISVpmv1, utilize structure-guided design to improve stability, yield, and the breadth of the immune response against polymorphic parasite strains.
- Other names
- HPISVpmv1HPISVpmv-1HPISVpmv 1PAMVACPRIMVACplacental malaria vaccinerID1-ID2a-M1010rID-1-ID2a-M1010rID 1-ID2a-M1010
02
Targets
PfEMP1 (Plasmodium falciparum erythrocyte membrane protein 1)
Beyond the preview
Go deeper on VAR2CSA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAR2CSA vaccine.